Related Experiment Video
Updated: Jun 5, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Sentinel node mapping in the prostate cancer. Meta-analysis
R Sadeghi1, K T Tabasi, S M M Bazaz
1Nuclear Medicine Research Center, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Ebn Sina Street, Mashhad, Iran. sadeghir@mums.ac.ir
Nuklearmedizin. Nuclear Medicine
|January 26, 2011
Summary
Sentinel lymph node (SLN) biopsy is a valuable tool for prostate cancer management. This meta-analysis confirms its high detection and sensitivity rates, potentially avoiding unnecessary pelvic lymph node dissections.
Area of Science:
- Urology
- Surgical Oncology
- Oncology
Background:
- Sentinel node (SN) biopsy is increasingly adopted for various cancers.
- Its application and efficacy in prostate cancer require comprehensive evaluation.
Purpose of the Study:
- To quantitatively synthesize the existing literature on sentinel lymph node biopsy in prostate cancer.
- To assess the detection rate and sensitivity of sentinel lymph node biopsy for prostate cancer staging.
Main Methods:
- Systematic literature search across multiple databases (Medline, SCOPUS, Google Scholar, Ovid, Springer, Science direct).
- Keywords used: "prostate" AND "sentinel" for studies on sentinel lymph node biopsy in prostate cancer.
- Inclusion criteria focused on studies reporting detection rate and sensitivity of the procedure.
Main Results:
- Pooled detection rate for sentinel lymph node biopsy was 93.8% (95% CI 89-96.6%) across 21 studies.
- Pooled sensitivity was 94% (95% CI 91-96%) based on 16 studies.
- High heterogeneity was observed for detection rate (I2 = 89.81%), but not for sensitivity (I2 = 0.0%).
Conclusions:
- Sentinel lymph node biopsy is a feasible procedure for prostate cancer.
- It demonstrates a high detection rate and sensitivity, with a low false negative rate.
- This technique can help prevent unnecessary pelvic lymph node dissections in prostate cancer patients.
